The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi ...

AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...

Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with ...

AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...

AstraZeneca's Imfinzi has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

(Alliance News) - AstraZeneca PLC on Monday said Imfinzi has been recommended for approval in the EU as monotherapy for limited-stage small cell lung cancer.

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

Panjim: The Goa Health Department, alongside AstraZeneca and Qure.ai, is launching multiple initiatives to improve cancer ...

London open The FTSE 100 is expected to open 109 points lower on Monday, having closed up 0.31% on Friday at 8,673.96.